The CAR T-cell therapy market was valued at $1,709.00 million in 2021, and is estimated to reach $6,093.10 million by 2031, growing at a CAGR of 13.5% from 2022 to 2031.
Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. During this treatment, healthcare professionals reprogram the immune system to attack cancer cells. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors. Healthcare professionals currently use CAR T-cell therapy to treat various types of cancer.
The CAR T-cell therapy market will show significant market growth during the forecast period owing to rise in prevalence of cancer, rise in demand for ideal therapeutics for treatment of cancer, and favorable reimbursement policies provided by manufacturers & insurance providers in some countries. However, higher cost of treatment, and stringent government regulation for approval of these therapeutics are expected to hamper the market growth. Furthermore, promising drugs in pipeline, expected approval of newer CART therapeutics, rise in number of target population with lack of ideal treatment, and surge in awareness regarding CART therapies are expected to significantly drive the market growth during the forecast period. In addition, technological advancements, launch of various products, and strategies among the key players such as acquisition, collaboration, and agreement drive the CAR T-cell therapy market growth.
The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.
The CAR T-cell therapy market is studied across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).
The major players profiled in the report are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.
Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment. During this treatment, healthcare professionals reprogram the immune system to attack cancer cells. CAR T-cell therapy is a type of cell-based gene therapy, because it involves altering the genes inside T-cells to help them attack the cancer. T-cells are part of the immune system. They are a type of white blood cell with proteins on the surface that act as receptors. Healthcare professionals currently use CAR T-cell therapy to treat various types of cancer.
The CAR T-cell therapy market will show significant market growth during the forecast period owing to rise in prevalence of cancer, rise in demand for ideal therapeutics for treatment of cancer, and favorable reimbursement policies provided by manufacturers & insurance providers in some countries. However, higher cost of treatment, and stringent government regulation for approval of these therapeutics are expected to hamper the market growth. Furthermore, promising drugs in pipeline, expected approval of newer CART therapeutics, rise in number of target population with lack of ideal treatment, and surge in awareness regarding CART therapies are expected to significantly drive the market growth during the forecast period. In addition, technological advancements, launch of various products, and strategies among the key players such as acquisition, collaboration, and agreement drive the CAR T-cell therapy market growth.
The CAR T-cell therapy market is segmented on the basis of drug type, indication, end user, and region. On the basis of drug type, the market is classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. By indication, the market is segregated into lymphoma, acute lymphocytic leukemia, and others. Depending on end user, it is fragmented into hospitals and cancer treatment centers.
The CAR T-cell therapy market is studied across North America (the U.S., and Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).
The major players profiled in the report are Autolus, Bluebird Bio-Inc., Bristol-Myers Squibb, Caribou Biosciences Inc., Cartesian Therapeutics, Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Merck & Co. Inc., Miltenyi Biotech, Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the car t-cell therapy market analysis from 2021 to 2031 to identify the prevailing car t-cell therapy market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the car t-cell therapy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global car t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Go To Market Strategy
- New Product Development/Product Matrix of Key Players
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis/Price Point Analysis
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By Drug type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By End user
- Hospitals
- Cancer Treatment Centers
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
- Autolus Therapeutics
- Bluebird Bio, Inc.
- Bristol-Myers Squibb
- Caribou Biosciences, Inc.
- Cartesian Therapeutics, Inc.
- Celgene Corporation
- Cellectis
- Celyad Oncology
- Gilead Sciences, Inc. (Kite Pharma Inc.)
- Intellia Therapeutics
- Juno Therapeutics, Inc.
- Merck & Co., Inc.
- Miltenyi Biotech
- Novartis AG
- Pfizer, Inc.
- Sorrento Therapeutics, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CAR T-CELL THERAPY MARKET, BY DRUG TYPE
CHAPTER 5: CAR T-CELL THERAPY MARKET, BY INDICATION
CHAPTER 6: CAR T-CELL THERAPY MARKET, BY END USER
CHAPTER 7: CAR T-CELL THERAPY MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “CAR T-Cell therapy Market," the car t-cell therapy market was valued at $1.7 billion in 2021, and is estimated to reach $6.1 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.Chimeric antigen receptor (CAR) T-cell therapy treats certain cancer by turning T-cells into more efficient cancer-fighting cells. CAR T-cell therapy is a novel targeted approach, which involves genetic engineering of T-cells to specifically target the receptors on cancer cells.
The benefits of CAR T-cell therapies over conventional drugs include, the destruction of cancer cells using patients' immune systemand early recovery. In addition, CAR T-cell therapy survives for a long time in the body. It has the ability to recognize and target cancer cells even if the cancer relapses. Therefore, CAR T-cell therapy is mainly used for the treatment of lymphoma, acute lymphocytic leukemia, and multiple myeloma blood cancer. Owing to its various advantage over conventional drugs, the CAR T-cell therapy products are expected to witness a high adoption rate, which eventually leads to growth in the CAR T-cell therapy market size.
Globally, the CAR T-cell therapy market share is witnessing significant growth, owing to increase in technological advancements, increase in prevalence of cancer, and favorable reimbursement policies in some countries, which are expected to create new opportunities for CAR T-Cell therapy market growth during the forecast period.
The COVID-19 outbreak is anticipated to have a negative impact on the market, as huge number of medical college and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The COVID-19 pandemic had a negative impact on the market because priority is given to COVID-19 patient for treatment. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19, resists the growth of CAR T-cell therapy market size. Decline in people transit, closing of borders, and confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market share. Nonessential surgical procedures took a potential backlog and home setting care was preferred, owing to rapidly rising COVID-19 cases, as only elective emergency surgeries were performed.
Therefore, this is anticipated to slowdown in market growth during the ongoing pandemic. However, owing to the introduction of various COVID-19 vaccination, people can readily reach out to hospital and cancer treatment centers, due to which surge in the demand of CAR T-cell therapy is expected in the near future. The demand of CAR T-cell therapy medicine is expected to increase, owing to surge in the R&D activities, rapidly expanding clinical trial activities, and recent commercialization of CAR-T cell therapy. Thus, such development is anticipated to bring stabilization and drive the CAR T-cell therapy market growth.
However, sales of CAR T-cell therapy market trends have witnessed hindrances, owing to the strict government regulations on the approval of CAR T-cell therapy. Side effects of CAR T-cell therapy and high cost of treatment also hamper the market growth.
By drug type, the axicabtagene ciloleucel segment was the highest revenue contributor to the market owing to increase in adoption of (Yescarta) axicabtagene ciloleucel for treatment of relapsed or refractory large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The brexucabtagene autoleucel segment is expected to witness highest CAGR during the forecast period, owing to rise in approval of CAR T-cell therapies in different countries for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
On the basis of indication, the lymphoma segment generated maximum revenue in 2021 owing to higher number of approved CAR T-cell therapeutics for treatment of different form of lymphoma with large number of target population. The acute lymphocytic leukemia segment is expected to witness highest CAGR during the forecast period, owing to increase in awareness of CAR T-cell therapeutics for treatment of ALL and expected launch of these drug for treatment of ALL.
On the basis of end user, the hospitals segment was the highest revenue contributor to the market in 2021, owing to factors, such as well-equipped operation theatre, higher buying power, and rise in patient admission. The cancer treatment centers segment is expected to witness highest CAGR during the forecast period, owing to availability of a wide range of choice of treatment and increase in number of cancer centers in some developing nations.
Region-wise, in CAR-T cell therapy industry, North America generated higher revenue in 2021, owing to strong presence of key players and availability of approved therapeutics with higher adoption of CAR T-cell therapies. Asia-Pacific is expected to witness highest CAGR during the forecast period owing to rise in awareness regarding CAR T-cell therapy, expected launch of CART drugs, and rise in the number of target population.
Key Findings of the Study
- By drug type, the axicabtagene ciloleucel segment held the largest share in the CAR T-cell therapy market in 2021.
- By indication, the lymphoma segment held the largest share in the CAR T-cell therapy market in 2021.
- By end user, the cancer centers segment is expected to show the fastest market growth during the forecast period.
- Region-wise, North America held the largest market share in 2021.
Companies Mentioned
- Autolus Therapeutics
- Bluebird Bio, Inc.
- Bristol-Myers Squibb
- Caribou Biosciences, Inc.
- Cartesian Therapeutics, Inc.
- Celgene Corporation
- Cellectis
- Celyad Oncology
- Gilead Sciences, Inc. (Kite Pharma Inc.)
- Intellia Therapeutics
- Juno Therapeutics, Inc.
- Merck & Co., Inc.
- Miltenyi Biotech
- Novartis AG
- Pfizer, Inc.
- Sorrento Therapeutics, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 219 |
| Published | December 2023 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1709 million |
| Forecasted Market Value ( USD | $ 6093.1 million |
| Compound Annual Growth Rate | 13.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
